Horizon scanning: Phase III safety study of once-daily fluticasone furoate plus vilanterol in the treatment of asthma

Source: Thorax Area: News The results of a Phase III study evaluating the safety of an investigational combination of fluticasone furoate and vilanterol in the treatment of asthma have been published early online in Thorax.   The authors note that long-acting ?2 agonists (LABA) are recommended in combination with inhaled corticosteroids (ICS) for patients with asthma who remain symptomatic on low-medium dose ICS alone. The ICS fluticasone furoate (FF), together with the LABA vilanterol (VI), are in development as a novel, once-daily ICS/LABA combination inhaler for asthma and chronic obstructive pulmonary disease.   The purpose of the current study was to evaluate the safety and tolerability of once daily treatment with two strengths of this investigational combination, in patients aged ?12 years with asthma. A total of 503 patients (intention-to-treat population) were randomised to double-blind (double-dummy) treatment with 100mcg FF/25mcg VI once daily in the evening (n=201), 200mcg ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news